Sign up USA
Proactive Investors - Run By Investors For Investors

Aldeyra Therapeutics reports positive results from a phase 2a trial of its treatment for dry eye disease

In a statement, the Nasdaq-listed company said that based on statistically and clinically significant activity across a number of sign and symptom endpoints and tolerability, the ADX-102 treatment was nominated for advancement
Dry eye treatment
The group said it now expects to initiate a phase 2b trial in the first half of 2018

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) saw its shares soar over 50% higher in premarket trade after the biotechnology company reported positive results from a phase 2a trial of its treatment for dry eye disease.

In a statement, the Nasdaq-listed company said that based on statistically and clinically significant activity across a number of sign and symptom endpoints and tolerability, the ADX-102 treatment was nominated for advancement.

The group said it now expects to initiate a phase 2b trial in the first half of 2018.

Aldeyra’s chief executive Todd Brady said: “These data represent the fourth set of positive phase 2 results with ADX-102 in ocular inflammation.

"The breadth of activity across noninfectious anterior uveitis, allergic conjunctivitis, and now dry eye disease confirms the potential of ADX-102 as an important and differentiated therapy in ophthalmology."

In reaction to the news, Aldeyra shares were up 52.38%, putting them on track to open at the highest level seen in over nine months.

View full ALDX profile View Profile

Aldeyra Therapeutics Timeline

Related Articles

woman at a microscope
September 04 2017
Lead product Lojuxta generated revenues of €5.75mln in the first-half
GW_Pharma.png
June 07 2017
Midatech has three lead R&D programmes: a carcinoid syndrome treatment; a liver cancer drug; and a brain cancer therapy
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use